Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development DAAN Biotherapeutics signed an exclusive licensing deal with LigaChem Biosciences for a tumor-targeting […]
Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in MTAP-deletion NSCLC The combination targets two complementary mechanisms in MTAP-deletion solid tumors, […]
Weekly Digest – February 2025 Weekly Digest – February 2025 11 February 2025: Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint inhibitor Ellipses Pharma will develop GENA-104 (EP0089), a first-in-class monoclonal antibody targeting […]
